This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Ian S. Zagon, MS, PhD; Matthew S. Klocek, MS; James W. Griffith, DVM; Joseph W. Sassani, MD, MHA; András M. Komáromy, DVM, PhD; Patricia J. McLaughlin, MS, DEd

Arch Ophthalmol. 2008;126(4):501-506.

Objective  To determine whether topical application of naltrexone prevents exuberant granulation tissue formation with neovascularization in diabetic rat corneas.

Methods  Diabetes was induced with streptozotocin. A 5-mm corneal abrasion at 9 or 11 weeks was treated topically for 7 days (4 times daily) with naltrexone or a sterile vehicle.

Results  Within 2 to 5 days after reepithelialization, diabetic rats given the sterile vehicle had a 41% incidence of corneal lesions represented by exuberant granulation tissue with corneal neovascularization extending from the limbus. These lesions exhibited edema, cellular and vascular inflammation, and disruption of stromal lamella by fibrovascular tissue and calcium mineralization, but infection was not detected. No corneal lesions were recorded in the diabetic group treated with naltrexone or the control group given the sterile vehicle. Diabetic rats with corneal lesions given the sterile vehicle reepithelialized more slowly than diabetic rats given the sterile vehicle without such lesions, but no difference in blood glucose levels were noted.

Conclusions  Using a minimally invasive model in diabetic rats, topical naltrexone normalizes corneal wound healing and prevents neovascularization.

Clinical Relevance  Direct application of naltrexone may serve as an important strategy for facilitating corneal healing and inhibiting corneal neovascularization.

Author Affiliations: Departments of Neural and Behavioral Sciences (Drs Zagon and McLaughlin and Mr Klocek), Comparative Medicine (Dr Griffith), and Ophthalmology (Dr Sassani), The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey; and the Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia (Dr Komáromy).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improved parameters of metabolic glycaemic and immune function and arterial stiffness with naltrexone implant therapy
Reece
BMJ Case Reports 2009;2009:bcr0820080799-bcr0820080799.
ABSTRACT | FULL TEXT